Utilizing Multiomic Advanced Diagnostics to Identify CDK 4/6 Inhibitor Response Predictors and a Post-treatment Multiomic Signature for Patients With ER+/HER2- Metastatic Breast Cancer

NCT03195192 · clinicaltrials.gov ↗
NA
Phase
COMPLETED
Status
28
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Side-Out Foundation

Collaborators